Overview

This trial is active, not recruiting.

Condition aortic valve stenosis
Treatment transcatheter aortic valve replacement
Phase phase 2
Sponsor Direct Flow Medical, Inc.
Start date August 2013
End date June 2014
Trial size 30 participants
Trial identifier NCT01932099, G120160, IP 011

Summary

A study to assess the safety and effectiveness of the Direct Flow Medical aortic valve system. This is for people with severe aortic stenosis who are not well enough to undergo a surgical repair. The delivery of this device is done via the femoral artery.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Prospective, multi-center, single arm feasibility study. Subjects will include patients with severe aortic valve stenosis who require replacement of their native aortic valve. The intervention is transcatheter aortic valve replacement.
transcatheter aortic valve replacement Direct Flow Medical aortic valve system
Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.

Primary Outcomes

Measure
Freedom from all cause mortality/Device success
time frame: 6 months post procedure

Secondary Outcomes

Measure
Early Safety
time frame: 30 Days
Clinical Efficacy
time frame: 6 months,and annually at 1 to 5 years
Time-related Valve Safety
time frame: 30 days, 6 months and annually at 1 to 5 years
Clinical Endpoints
time frame: 30 days, 6 months and annually at 1 to 5 years.

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: 1. The patient has severe senile degenerative aortic valve stenosis determined by resting or dobutamine stress echocardiogram and Doppler, or simultaneous pressure recordings at cardiac catheterization defined as: mean gradient >40 mmHg or peak jet velocity >4.0 m/s and an aortic valve area ≤0.8 cm2 or aortic valve area index ≤0.5 cm2/m2. 2. The patient has moderate to severe symptoms from aortic valve stenosis (NYHA Functional Class ≥III). 3. The patient must have a predicted risk of operative mortality or serious irreversible morbidity of >50% at 30 days, or be deemed not suitable for surgery for other reasons. This conclusion shall be based on consensus of one cardiologist and two cardiac surgeons at the investigational site after careful consideration of the patient's STS risk score and co-morbidities, and after at least one of the surgeons participating in the decision has personally examined the patient. 4. The patient been informed of the nature of the study, agrees to its provisions, is willing to comply with protocol-specified follow-up evaluations and has provided written informed consent, approved by the appropriate IRB. Exclusion Criteria 1. Left ventricular ejection fraction (LVEF) <20% determined by resting echocardiogram 2. Patients with an acute MI within 30 days preceding the index procedure. 3. Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the study procedure 4. Patients with impaired renal function (estimated Glomerular Filtration Rate [eGFR] <20cc/min, calculated from serum creatinine by the Cockcroft-Gault formula) 5. Patients with a platelet count of <50,000 cells/mm³ or a WBC < 1000 cells/mm³ within 7 days prior to index procedure. 6. Patients with a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated, or who will refuse transfusion. 7. Patients who have received any organ transplant or are on a waiting list for any organ transplant. 8. Patients with known other medical illness (e.g. carcinomas, chronic liver disease, chronic renal disease or chronic end stage pulmonary disease) or known history of substance abuse that may cause non-compliance with the protocol, confound the data interpretation or is associated with a life expectancy of less than one year, or expectation that patient will not improve despite treatment of aortic stenosis. 9. Patients with known hypersensitivity or contraindication to aspirin, heparin, clopidogrel/ticlopidine, and/or contrast sensitivity that cannot be adequately pre-medicated. 10. Patients with a history of a stroke or transient ischemic attack (TIA) within the prior 6 months. 11. Patients with an active gastrointestinal (GI) bleeding within the prior 6 months. 12. Patients presenting with hemodynamic instability or cardiogenic shock defined by low cardiac output, vasopressor dependence, or mechanical hemodynamic support. 13. Patients who have a planned treatment with any other investigational device or procedure during the study period, or who are currently participating in an investigational drug or another device trial 14. Any planned surgical, percutaneous coronary or peripheral procedure to be performed prior to the 30 day follow-up from the TAVR procedure. 15. Untreated clinically significant coronary artery disease requiring revascularization 16. Trans-esophageal echocardiography (TEE) is contraindicated 17. Active endocarditis or sepsis within 6 months prior to the study procedure 18. Dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits) 19. Congenital bicuspid or unicuspid valve determined by echocardiography 20. Prior aortic or mitral valve surgery or pre-existing prosthetic heart valve in any position 21. Native valve annulus diameter is <19mm or >26mm determined by the screening CT scan 22. Extreme asymmetrical calcification of the native aortic valve determined by the screening CT scan 23. Echocardiographic evidence of intra-cardiac mass, thrombus, vegetation, or spontaneous echo contrast in the left atrium 24. >3+ aortic regurgitation, mitral regurgitation or tricuspid regurgitation 25. Moderate to severe mitral stenosis 26. Thoracic aortic aneurysm (TAA) or abdominal aortic aneurysm (AAA) >5.0 cm 27. Presence of an endovascular stent graft for treatment of AAA or TAA 28 Hypertrophic obstructive cardiomyopathy 29. Patients with severe peripheral arterial disease that precludes sheath vascular access (e.g. luminal diameter less than 6.5 mm, severe obstructive calcification or severe tortuosity)

Additional Information

Official title The Direct Flow Medical TranScatheter Aortic Valve RepLacement System US Feasibility Trial
Principal investigator E. Murat Tuzcu, MD
Description The Direct Flow Medical Transcatheter Aortic Valve System is indicated for symptomatic patients who require replacement of their native aortic valve and have a predicted operative mortality or serious morbidity risk of equal or greater 50% at 30 days with surgical aortic valve replacement or are deemed unsuitable for surgery.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Direct Flow Medical, Inc..